Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Trimmed by Leavell Investment Management Inc.

Posted by on Jun 25th, 2023

Leavell Investment Management Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 9.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,913 shares of the biopharmaceutical company’s stock after selling 390 shares during the period. Leavell Investment Management Inc.’s holdings in Gilead Sciences were worth $325,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Vestmark Advisory Solutions Inc. lifted its holdings in shares of Gilead Sciences by 4.7% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,995 shares of the biopharmaceutical company’s stock valued at $1,717,000 after purchasing an additional 897 shares during the last quarter. HB Wealth Management LLC lifted its stake in Gilead Sciences by 24.0% in the 4th quarter. HB Wealth Management LLC now owns 11,007 shares of the biopharmaceutical company’s stock worth $945,000 after acquiring an additional 2,129 shares in the last quarter. Dfpg Investments LLC purchased a new stake in Gilead Sciences in the 4th quarter worth about $226,000. CTC Capital Management LLC lifted its stake in Gilead Sciences by 517.1% in the 4th quarter. CTC Capital Management LLC now owns 25,300 shares of the biopharmaceutical company’s stock worth $2,172,000 after acquiring an additional 21,200 shares in the last quarter. Finally, Greenleaf Trust lifted its stake in Gilead Sciences by 2.3% in the 4th quarter. Greenleaf Trust now owns 36,034 shares of the biopharmaceutical company’s stock worth $3,094,000 after acquiring an additional 800 shares in the last quarter. 81.59% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

GILD opened at $77.47 on Friday. The firm has a market capitalization of $96.63 billion, a P/E ratio of 17.49, a price-to-earnings-growth ratio of 0.91 and a beta of 0.39. The stock’s 50 day moving average price is $79.46 and its two-hundred day moving average price is $82.17. The company has a quick ratio of 1.13, a current ratio of 1.28 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12-month low of $59.27 and a 12-month high of $89.74.

Gilead Sciences (NASDAQ:GILD – Get Rating) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.26). The business had revenue of $6.35 billion during the quarter, compared to analyst estimates of $6.33 billion. Gilead Sciences had a net margin of 20.65% and a return on equity of 39.35%. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period last year, the business earned $2.12 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 6.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Thursday, June 15th will be given a $0.75 dividend. The ex-dividend date is Wednesday, June 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.87%. Gilead Sciences’s dividend payout ratio is currently 67.72%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 1,485 shares of the firm’s stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $76.90, for a total value of $114,196.50. Following the completion of the sale, the insider now owns 29,402 shares in the company, valued at approximately $2,261,013.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on GILD shares. StockNews.com started coverage on Gilead Sciences in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. BMO Capital Markets raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $90.00 to $100.00 in a research note on Tuesday, May 16th. Royal Bank of Canada reduced their price objective on Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating for the company in a research note on Monday, March 6th. Finally, Morgan Stanley raised their price target on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 12th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.00.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.